Propranolol Hydrochloride + DiazepamThird Party Manufacturing in India

Propranolol Hydrochloride plus Diazepam combines a non-selective beta-adrenergic receptor antagonist with a long-acting benzodiazepine to provide comprehensive control of anxiety and its somatic manifestations. Propranolol competitively blocks beta-1 and beta-2 adrenergic receptors throughout the body. Beta-1 blockade in the heart reduces heart rate, myocardial oxygen demand, and cardiac output, effectively counteracting the sympathetic overdrive that drives physical anxiety symptoms. Its high lipophilicity allows propranolol to penetrate the central nervous system, where it modulates noradrenergic transmission in brain regions involved in fear and anxiety processing, including the locus coeruleus and amygdala. Diazepam acts as a positive allosteric modulator at the GABA-A receptor complex, binding to the benzodiazepine site and enhancing the affinity of GABA for its receptor. This results in increased frequency of chloride channel opening, greater chloride ion influx, and enhanced neuronal inhibition. Diazepam differs from other benzodiazepines in its long elimination half-life and the formation of active metabolites including nordiazepam, which contributes to sustained anxiolytic coverage. The combination allows for reduced benzodiazepine dosing by leveraging the beta-blocker's ability to control peripheral anxiety symptoms, potentially lowering the risk of tolerance and dependence associated with high-dose benzodiazepine monotherapy.

Therapeutic Uses

Propranolol Hydrochloride + Diazepam combination is prescribed for:

• Generalised Anxiety Disorder with Somatic Symptoms: This combination is particularly effective in patients whose anxiety presents with prominent physical complaints such as palpitations, chest tightness, tremors, and gastrointestinal discomfort. Diazepam addresses the central anxiety component while propranolol controls the peripheral autonomic manifestations.

• Alcohol Withdrawal Syndrome: The combination is used in the management of alcohol withdrawal, where propranolol reduces autonomic hyperactivity and diazepam provides the requisite anticonvulsant and anxiolytic coverage.

• Phobic Anxiety Disorders: In patients with phobic disorders where anticipatory anxiety triggers significant sympathetic activation, the dual mechanism provides both symptomatic relief and facilitates behavioural engagement.

• Psychosomatic Cardiovascular Symptoms: For patients presenting with anxiety masquerading as cardiac symptoms such as palpitations and non-anginal chest pain, the combination offers both diagnostic and therapeutic benefits.

• Insomnia Associated with Anxiety: Diazepam's longer duration of action provides sustained sedation in patients with sleep disturbance due to anxiety, while propranolol reduces nocturnal sympathetic arousal.

Why Manufacturers Choose Propranolol Hydrochloride + Diazepam

Propranolol + Diazepam is a well-established combination in the Indian pharmaceutical market with consistent demand from general practitioners and psychiatrists. Diazepam is included in the WHO Model List of Essential Medicines, reinforcing its clinical indispensability. The combination is commonly manufactured as tablets for third-party PCD franchise distribution. Both APIs are readily available from domestic manufacturers, ensuring cost-effective production. Indian WHO-GMP certified facilities regularly manufacture this combination for both domestic and export markets, particularly in Africa and Southeast Asia. The molecule combination offers manufacturers a dependable product with repeat prescription patterns typical of chronic anxiety management.